347850.KQ D&D Pharmatech Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
23:12
May 27
May 27
DND Pharmatech clinical results may trigger big pharma acquisition.
DND Pharmatech's 48-week clinical results for its obesity treatment are highly positive, and five big pharma companies are interested in acquiring the asset. Speaker expects a multi-trillion won contract (similar to previous deals by ABL Bio) and believes the stock has more upside, suggesting it is not over yet despite the recent rally.
MED
11:00
May 27
May 27
License-out catalyst, massive upside potential.
DND Pharmatech has outstanding phase 2 data for its obesity treatment and a license-out event is imminent. Market cap could rise to at least 5 trillion won from the current 3.3 trillion, comparable to existing MASH therapy developers worth ~13 trillion won.
HIGH
07:00
May 27
May 27
DND Pharmatech binary ASCO catalyst.
DND Pharmatech has a binary catalyst from ASCO data release expected on the afternoon of the recording. If the clinical data is positive, the stock could surge sharply, and if it also raises expectations for technology exports, further upside is possible. Investors should monitor the event closely.
MED
08:25
May 22
May 22
Watch DND Pharmatech for ASCO data catalyst.
DND Pharmatech should be watched ahead of its 48-week obesity drug data presentation at the diabetes conference on May 27. Previous 12-week and 24-week results were very strong, and a positive outcome could lead to technology export and a significant share price move.
MED
About 347850.KQ Analyst Coverage
Buzzberg tracks 347850.KQ (D&D Pharmatech Inc.) across 2 sources. 2 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (50%). 4 total trade ideas tracked.